Learn how the 12-year biologic exclusivity rule under the BPCIA delays biosimilar entry, impacting drug prices and patient access in the US compared to global markets.
Jun, 4 2026
Jul, 29 2026
Dec, 3 2025
Dec, 29 2025
Jan, 5 2026